Amed Co., Ltd.
Amed Co., Ltd. engages in the research and development, manufacture, and trading of medical equipment in Taiwan. It offers wound care dressing products under the HERADERM brand name; negative pressure wound therapy systems that provides 24-hour oxygen supply to wounds under the Genadyne brand name; and wound treatment systems under the Natrox brand name. The company also provides 7-day long-actin… Read more
Amed Co., Ltd. (7575) - Net Assets
Latest net assets as of June 2025: NT$368.05 Million TWD
Based on the latest financial reports, Amed Co., Ltd. (7575) has net assets worth NT$368.05 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.16 Billion) and total liabilities (NT$786.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$368.05 Million |
| % of Total Assets | 31.87% |
| Annual Growth Rate | 18.86% |
| 5-Year Change | 95.95% |
| 10-Year Change | N/A |
| Growth Volatility | 12.49 |
Amed Co., Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Amed Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amed Co., Ltd. (2019–2024)
The table below shows the annual net assets of Amed Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$406.24 Million | -4.65% |
| 2023-12-31 | NT$426.04 Million | +27.44% |
| 2022-12-31 | NT$334.31 Million | +30.05% |
| 2021-12-31 | NT$257.06 Million | +23.99% |
| 2020-12-31 | NT$207.32 Million | +21.09% |
| 2019-12-31 | NT$171.21 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amed Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 276.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$78.23 Million | 19.26% |
| Common Stock | NT$300.00 Million | 73.85% |
| Other Components | NT$28.02 Million | 6.90% |
| Total Equity | NT$406.24 Million | 100.00% |
Amed Co., Ltd. Competitors by Market Cap
The table below lists competitors of Amed Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CGPVD
PINK:CGPVD
|
$8.00K |
|
Lucky Core Ind. Ltd
KAR:LCI
|
$8.00K |
|
Ordinary Fully Paid For Exempt Nzx Deferred Sett
AU:TWRDC
|
$8.00K |
|
Vantage Corp
NYSE MKT:VNTG
|
$8.01K |
|
SinglePoint Inc
PINK:SING
|
$7.98K |
|
Petrotx - Limited Partnership
TA:PTX
|
$7.98K |
|
United Motors Lanka PLC
CM:UMLN0000
|
$7.97K |
|
AFBL
PINK:AFBL
|
$7.97K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amed Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 426,039,000 to 406,242,000, a change of -19,797,000 (-4.6%).
- Net income of 55,203,000 contributed positively to equity growth.
- Dividend payments of 75,000,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$55.20 Million | +13.59% |
| Dividends Paid | NT$75.00 Million | -18.46% |
| Total Change | NT$- | -4.65% |
Book Value vs Market Value Analysis
This analysis compares Amed Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.73x to 2.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$5.87 | NT$27.80 | x |
| 2020-12-31 | NT$6.91 | NT$27.80 | x |
| 2021-12-31 | NT$8.47 | NT$27.80 | x |
| 2022-12-31 | NT$11.12 | NT$27.80 | x |
| 2023-12-31 | NT$14.17 | NT$27.80 | x |
| 2024-12-31 | NT$13.50 | NT$27.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amed Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.59%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.77%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 2.82x
- Recent ROE (13.59%) is below the historical average (19.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 19.37% | 8.02% | 0.71x | 3.38x | NT$16.05 Million |
| 2020 | 17.42% | 7.60% | 0.75x | 3.04x | NT$15.38 Million |
| 2021 | 19.35% | 8.90% | 0.76x | 2.88x | NT$24.03 Million |
| 2022 | 23.11% | 11.20% | 0.83x | 2.47x | NT$43.82 Million |
| 2023 | 21.53% | 12.01% | 0.86x | 2.08x | NT$49.11 Million |
| 2024 | 13.59% | 6.77% | 0.71x | 2.82x | NT$14.58 Million |
Industry Comparison
This section compares Amed Co., Ltd.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,796,147,300
- Average return on equity (ROE) among peers: 10.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amed Co., Ltd. (7575) | NT$368.05 Million | 19.37% | 2.14x | $7.99K |
| St.Shine Optical Co Ltd (1565) | $5.39 Billion | 29.48% | 0.60x | $147.19 Million |
| Nang Kuang Pharmaceutical Co Ltd (1752) | $2.19 Billion | 9.94% | 0.50x | $46.91 Million |
| Maxigen Biotech Inc (1783) | $1.14 Billion | 7.68% | 0.11x | $53.63 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $107.95 Million |
| Bioteque (4107) | $1.88 Billion | 15.46% | 0.25x | $198.92 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 12.60% | 0.47x | $41.85 Million |
| Sunder Biomedical Tech. Co., Ltd. (4115) | $790.45 Million | 1.68% | 0.80x | $2.11K |
| BenQ Medical Technology (4116) | $1.10 Billion | 2.62% | 0.78x | $25.45 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.26 Billion | 10.49% | 0.61x | $128.74 Million |
| Unicon Optical Co., Ltd. (4150) | $963.23 Million | 21.57% | 0.59x | $22.68 Million |